Page	1	of	6

		FORM P	TO-1449		ATTY. DOCKET NO. APPLICATION NO. 0652.1710000 09/077,214					
				MENT	APPLICANT SCHMIDT et al.					
<u>IN</u>	FORMA11C	N DISC	LOSURE STATE	MENI.	FILING DATE May 26, 1998	GROUP To be	assigned			
				U.S.	PATENT DOCUMENTS	10 00				
EXAMINER		Ţ								
INITIAL		DOCUM	IENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE	=	
	AA	 	-		() () () () () () () () () ()	 	l			
	AB AC	-			NPR - 6 1993					
······	AD	_			\ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	 				
	AE	-				 				
	AF	 	·		AT & TRANS					
	AG					<u> </u>				
	AH									
	AI									
	AJ									
	AK									
				FOREI	GN PATENT DOCUMENTS					
EXAMINER INITIAL		DOCUM	MENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATIO		
/ ورا	AL1	40- 92	2/20356	11/26/1992	WIFE- WO				Yes No	
PB3	AM1	EP 0	569 678	11/18/1993	Europe				Yes No	
(m)	AN1	Wer 94	4/05304 t /	03/17/1994	wife VO				Yes No	
V3 1	AO1_	₩ 0- 94	4/21808 1	09/29/1994	MILE 10			Abstract	Yes No	
m1	AP1	W 01 94	4/23031	10/13/1994	WIPO W6				Yes No	
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)										
m	AR	1	Baskar, S., Immunity in	et al., "MHC Cla Autologous Mice	ass II-Transfected Tumor Cells I ," Cell. Immunol. 155:123-133 (A	nduce Long-T oril 1994).	erm Tumor-Sp	pecific /	<i>,</i>	
m/	AŞ ▼	Dranoff, G., et al., "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity," Proc. Natl. Acad. Sci. USA 90:3539-3543 (April 1993).								
M	AT 1 Dranoff, G., and Mulligan, R.C., "Gene Transfer as Cancer Therapy," Adv. Immunol. 58:417-454 (February 1995).									
EXAMINER	7					DATE CONSID	ERED 8/	10/20-		
EXAMINER: Initiation if no	tial if t in cor	refere	ence consider ace and not c	ed, whether or n onsidered. Incl	ot citation is in conformance wi ude copy of this form with next	th MPEP 609.	Draw line on to Applic	through		

Page 2 of 6

			· · · · · · · · · · · · · · · · · · ·					. 430 2 01 0	
			_		ATTY. DOCKET NO. 0652.1710000		APPLICATION NO. 09/077,214		
			TO-1449	-145514	APPLICANT SCHMIDT et al.				
<u>IN</u>	FORMATIC	<u>N</u> DISC	CLOSURE STATE	MENT	FILING DATE May 26, 1998	FILING DATE GROUP			
				U.S.	PATENT DOCUMENTS				
EXAMINER			,, ,						
INITIAL		DOCUM	MENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE	
	AA								
	AB AC						+		
	AD				OE JCO				
	AE								
	AF	<u> </u>			6 199				
	AG				IRR S				
	AH								
	ΑI	1			ATENT & TRADE				
	AJ								
	AK								
				FOREI	GN PATENT DOCUMENTS				
EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
(M)	AL2	-₩0- 9:	5/00159	01/05/1995	MIPO. WO			Yes No	
	АМ							Yes No	
	AN							Yes No	
	AO							Yes No	
	AP							Yes No	
-		<u> </u>	OTHER (Including Author	, Title, Date, Pertinent Pages,	etc.)	<u>-</u>	•	
m	OTHER (Including Author, Title, Date, Pertinent Pages, etc.) AR R R Kärre, K., et al., "Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy," Nature 319:675-678 (February 1986).								
WI	AS	Mandelboim, O., et al., "CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma," Nature 369:67-71 (May 1994).							
\sim	AT	Mandelboim, O., et al., "Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides," Nature Medicine 1:1179-1183 (November 1995).							
EXAMINER	V		5			DATE CONSI	DERED 81	wron	
EXAMINER: Init	tial if	refere	ence consider ace and not c	ed, whether or n	ot citation is in conformance w ude copy of this form with next	ith MPEP 60 communicat). Draw line	through	

Page 3 of 6

,					ATTY. DOCKET NO. APPLICATION NO. 0652.1710000 09/077,214					
71)			PTO-1449	- NAT N.Y	APPLICANT SCHMIDT <i>et al</i> .					
110	FORMAT IC	DN DIS	CLOSURE STATE	<u> </u>	FILING DATE GROUP May 26, 1998 To be assigned					
				U.S.	PATENT DOCUMENTS		DC 4351giic			
EXAMINER INITIAL		DOCII	MENT NUMBER	DATE	NAME	SI ASS	CUD CLACO	ELLING DATE		
INITIAL	AA	1000	MENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE		
	AB									
	AC				JC60					
	AD				/Q * a *E					
	AE	ļ								
	AF	<u> </u>			0	<u> </u>				
1.00	AG	├—								
	AH	<u> </u>			TENTS					
	AI	 				-				
	AK AK	╁				+				
	I AK	<u></u>		FORET	GN PATENT DOCUMENTS			L <u>.</u>		
EXAMINER		T		TOKET	IN TATERT DOCUMENTO	<u> </u>				
INITIAL		DOCU	MENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION		
	AL							Yes No		
	АМ							Yes No		
	AN							Yes No		
		<u> </u>						Yes		
	AO							No Yes		
	AP	<u> </u>	OTUED (Including Author	Title Date Dentinent Descri	-4 >		No		
			OTHER (Including Author,	, Title, Date, Pertinent Pages,	etc.)	·			
	AR (3	Nabel, G.J., biologic act (December 19	tivity, and lack	gene transfer with DNA-liposom of toxicity in humans," <i>Proc.</i> N	me complex latl. Acad	es in metanoma: . Sci. USA 90:1	Expression, 1307-11311		
m	AS	<u>3</u>	Oettgen, H.F., and Old, L.J., "Chapter 6. The History of Cancer Immunotherapy," in: <i>Biologic Therapy of Cancer</i> , DeVita, Jr., V.T., et al., Eds., J.B. Lippincott Co., Philadelphia, pp. 87-119 (1991).							
N3/	AT 4	Ostrand-Rosenberg, S., "Tumor immunotherapy: the tumor cell as an antigen-presenting cell," Curr. Opin. Immunol. 6:722-727 (October 1994).								
EXAMINER	V	1				DATE CON	SIDERED 3/	10/20cm		
					ot citation is in conformance wi					

									Page 4 of 6		
					ATTY. DOCKET NO. 0652.1710000 APPLICATION NO. 09/077,214						
		FORM	PTO-1449		APPLICANT SCHMIDT et al.						
<u>II</u>	IFORMATI!	ON DIS	SCLOSURE STATE	<u>EMENT</u>	FILING DATE GROUP						
					May 26, 1998		To be	assigned	 		
EXAMINER	T	T-		<u>u.s</u>	. PATENT DOCUMENTS			Γ			
INITIAL		DOC	JMENT NUMBER	DATE	NAME	CLA	ss	SUB-CLASS	FILING DATE		
	AA	-									
	AB	 		<u> </u>	<u> </u>						
	AC AD	+-									
	AE	 		-	910			<u> </u>			
	AF	T			400						
	AG				APR 6 1999 8						
	AH	1_			6 1999						
	AI	-			QUEMANS OF			ļ			
	AJ				Come						
	AK			FORE	CH DATENT DOCUMENTS			L			
EXAMINER	1	T		FOREI	GN PATENT DOCUMENTS			1			
INITIAL		DOC	UMENT NUMBER	DATE	COUNTRY	CLA	ss	SUB-CLASS	TRANSLATION		
	AL								Yes No		
	АМ	1							Yes No		
	AN								Yes No		
	AO								Yes No		
	AP								Yes No		
			OTHER (Including Author	, Title, Date, Pertinent Pa	ages, etc.)	1	<u> </u>	<u> </u>		
W31	AR J	4 Pardoll, D.M., "Cancer vaccines," Immunol. Today 14(6):310-316 (1993).									
m	AS 🛫	<u>4</u>	Plautz, G.E Natl. Acad.	Plautz, G.E., et al., "Immunotherapy of malignancy by in vivo gene transfer into tumors," Proc. Natl. Acad. Sci. USA 90:4645-4649 (May 1993).							
My	AT 😜	4	Schmidt, W. USA 92:4711	Schmidt, W., et al., "Cancer vaccines: The interleukin 2 dosage effect," Proc. Natl. Acad. Sci. USA 92:4711-4714 (May 1995).							
EXAMINER	1/					DATE	CONSIDE	FRED / 10/	ren		
					ot citation is in conformar	nce with MP	EP 609.	Draw line	through		
					ude copy of this form with						
						•					

.

Page 5 of 6

INITIAL AA AA AB AC AC AC AC AC AC AC	FORM PTO-1449 INTORNATION DISCLOSURE STATEMENT SCHILDT of al. Filling DATE GROUP To be assigned										Page 3 01 6
APPLICANT INFORMATION DISCLOSURE STATEMENT SEMENTS & 2.0. U.S. PATENT DOCUMENTS EXAMINER DOCUMENT MUMBER DATE NAME U.S. PATENT DOCUMENTS CLASS SUB-CLASS FILING DATE LATE SUB-CLASS FILING DATE CLASS SUB-CLASS FILING DATE COUNTRY CLASS SUB-CLASS TRANSLATION YES NO AN AN AN AN AN AN AN AN AN	APPLICANT SCHILDTONE STATEMENT SUBSTRICT SCHILDTONE STATEMENT SUBSTRICT SCHILDTONE STATEMENT SUBSTRICT SCHILDTONE SUBSTRICT						ATTY. DOCKET NO. APPLICATION NO.				
FILING DATE SAME SUB-CLASS FILING DATE	FILING DATE WAY 26, 1998 COUMENT WANTER U.S. PATENT DOCUMENTS XAMINER WITHAL AA AB AC AC AC AC AC AC AC AC										
EXAMINER AA AB AC AC AC AC AC AC AC AC	WANTER WANTER WANTER WITHAL AA AB AC AC AC AC AC AC AC AC	IN	FORMAT I	ON DIS	CLOSURE STATE	MENT					
EXMINER DOCUMENT NUMBER DATE NAME CLASS SUB-CLASS FILING DATE	DOCUMENT NUMBER DATE NAME CLASS SUB-CLASS FILING DATE AA AB AC					<u></u>				assigned	
INITIAL AA AA AB AC AC AC AC AC AC AC	NITIAL AA AA AA AB AC AD AC AC AC AC AC AC AC AC					U.:	S. PATENT DOCUMENTS			_	
AB AC AD AE AF AG AG AN AN AN AI AI AL AX FOREIGN PATENT DOCUMENTS EXAMINER NO AN AN AN AN AN CLASS SUB-CLASS TRANSLATION Yes No AN AN AN AN AN AN AN AN AN	AS AC	EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	NAME	с	LASS	SUB-CLASS	FILING DATE
AC AD AE AF AF AG AN AN AI AI AI AI AX FOREIGN PAIENT DOCUMENTS EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION Yes No AM AN AN AN TRANSLATION Yes No Yes No Yes No AN AN AN AN AN AN AN AN AN	AC AD AE AF AF AF AG AN AN AN AN AN AN AN AN AN		AA	<u> </u>						<u> </u>	
AD AE AF AG AG AN AI AI AI AI AI AL BOUNTRY AN AN AN AN AN AN AN AN AN A	AD AE AF AG AN AI AI AJ AX FOREIGN PATENT DOCUMENTS EXAMINER NITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION Yes No AN AN AN AN Transloading of tumor cells with foreign major histocompatibility complex No Yes No AP OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Schmidt, M., et al., "Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: A novel general strategy for the generation of potent cancer vaccines," Proc. Natl. Acad. Sci. USA 93:9759-9763 (September 1996). Wan Pel, A., and Boon, T., "Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis," Proc. Natl. Acad. Sci. USA 79:4718-4722 (August 1982). EXAMINER EXAMINER DATE CONSIDERED LEXAMORE LEXAMORER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through		AB							<u> </u>	
AR AF AG AG AH AI AI AI AI AN AK FOREIGN PATENT DOCUMENTS EXAMINER AN AN AN AN AN AN AN AN AN A	AR		AC							ļ	
AR AND S 1899 S AND	ARD S 1999 3 AND AS 1999 3 AND AS 1999 3 AND AS 1999 3 AND AR AR ARD AS 1999 3 AND AR AR ARD ARENT DOCUMENTS EXAMINER NITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION Yes No Yes No AND Yes No Transloading of tumor cells with foreign major histocompatibility complex class i peptide ligand: A novel general strategy for the generation of potent cancer vaccines, " Proc. Natl. Acad. Sci. USA 93:9759-9763 (september 1996). AS 1 Van Pel, A., and Boon, T., "Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis," Proc. Natl. Acad. Sci. USA 79:4718-4722 (August 1982). EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through		AD	 	_			\		<u> </u>	
AG AH AH AI AJ AJ AK FOREIGN PATENT DOCUMENTS EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION YES NO AM YES NO AM AN	AG AI AI AI AJ AX FOREIGN PATENT DOCUMENTS EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION Yes No AN AN AN OTHER (Including Author, Title, Date, Pertinent Pages, etc.) OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Froc. Natl. Acad. Sci. USA 93:9759-9763 (September 1996). WAN AS Van Pel, A., and Boon, T., "Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis," Proc. Natl. Acad. Sci. USA 79:4718-4722 (August 1982). AT Zatloukal, K., et âl., "Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'," Gene 135:199-207 (1993). EXAMINER: Initial if reference considered, whether or not citation is in conformance with NPEP 609. Draw line through		AE	<u> </u>				<u>~</u>			[
AN A	AN AN PORTION PATENT DOCUMENTS EXAMINER NITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION AL Yes No AN Yes No AN Yes No AN Yes No AP OTHER (including Author, Title, Date, Pertinent Pages, etc.) Schmidt, W., et al., "Transloading of tumor cells with foreign major histocompatibility complex class i peptide ligand: A novel general strategy for the generation of potent cancer vaccines," Proc. Natl. Acad. Sci. USA 93:9759-9763 (September 1996). AS 2 Van Pel, A., and Boon, T., "Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis," Proc. Natl. Acad. Sci. USA 79:4718-4722 (August 1982). EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through		AF	<u> </u>			App - \$ 1999				
AI AJ AK FOREIGN PATENT DOCUMENTS EXAMINER INITIAL AL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION Yes No Yes No AN AN Yes No Yes N	FOREIGN PATENT DOCUMENTS EXAMINER NITIAL AL AN AN AN AN AN AN AN AN		AG								
FOREIGN PATENT DOCUMENTS EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY AL AN AN AN OTHER (Including Author, Title, Date, Pertinent Pages, etc.)	FOREIGN PATENT DOCUMENTS EXAMINER NITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION AL AM Yes No AN Yes No AN Yes No OTHER (Including Author, Title, Date, Pertinent Pages, etc.) OTHER (Including Author, Title, Date, Pertinent Pages, etc.) For No OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Yes No OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Yes No OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Yes No OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Yes No OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Yes No OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Yes No OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Zohn An AR Schill, No, et al., "Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: A novel general strategy for the generation of potent cancer vaccines," Proc. Natl. Acad. Sci. USA 93:9759-9763 (September 1996). Yes No OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Zohn An AR Schill, No, et al., "Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: A novel general strategy for the generation of potent cancer vaccines," Proc. Natl. Acad. Sci. USA 93:9759-9763 (September 1996). Yes No OTHER (Including Author, Title, Date, Pertinent Pages, etc.) DATE CONSIDERED		АН	ļ				<u>\$</u>		ļ	ļ
EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION Yes No AM AM AM AN OTHER (Including Author, Title, Date, Pertinent Pages, etc.)	FOREIGN PATENT DOCUMENTS EXAMINER NITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION Yes No Yes No AN AN OTHER (Including Author, Title, Date, Pertinent Pages, etc.) OTHER (Including Author, Title, Date, Pertinent Pages, etc.) AR Schmidt, W., et al., "Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: A novel general strategy for the generation of potent cancer vaccines," Proc. Natl. Acad. Sci. USA 93:9759-9763 (september 1996). Van Pel, A., and Boon, T., "Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis," Proc. Natl. Acad. Sci. USA 79:4718-4722 (August 1982). Zatloukal, K., et al., "Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'," Gene 135:199-207 (1993). EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through		AI	↓			TRADEMIN				
EXAMINER EXAMINER EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION Yes No Yes No AM AN OTHER (Including Author, Title, Date, Pertinent Pages, etc.) OTHER (Including Author, Title, Date, Pertinent Pages, etc.) TOTHER (Including Author, Title, Date, Pertinent Pages, etc.) AR Schmidt, W., et al., "Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: A novel general strategy for the generation of potent cancer vaccines," Proc. Natl. Acad. Sci. USA 33:9759-9763 (September 1996). AS Zatloukal, K., et al., "Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'," Gene 135:199-207 (1993). EXAMINER DATE CONSIDERED LEARNS.	FOREIGN PATENT DOCUMENTS XXMINER INITIAL DOCUMENT NUMBER AL AL AL AL AN AN AN AN AN AN		AJ								
EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION Yes No Yes No AM AN OTHER (Including Author, Title, Date, Pertinent Pages, etc.) OTHER (Including Author, Title, Date, Pertinent Pages, etc.) AR Class TRANSLATION Yes No Yes No Yes No AP OTHER (Including Author, Title, Date, Pertinent Pages, etc.) AR Class I peptide ligand: A novel general strategy for the generation of potent cancer vaccines," Proc. Natl. Acad. Sci. USA 93:9759-9763 (September 1996). AS Van Pel, A., and Boon, T., "Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis," Proc. Natl. Acad. Sci. USA 79:4718-4722 (August 1982). EXAMINER DATE CONSIDERED SOFT	DOCUMENT NUMBER DATE COUNTRY AL AL AM AN AN AN AN AN AN AN AN AN		AK							<u> </u>	
AL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION AL YES NO YES NO AN YES NO AN	DOCUMENT NUMBER DATE COUNTRY AL AL AN AN AN AN AN AN AN AN		···			FORE	IGN PATENT DOCUMENTS				· · · · · · · · · · · · · · · · · · ·
AL No Yes No Yes	AN			DOCU	MENT NUMBER	DATE	COUNTRY		LASS	SUB-CLASS	TRANSLATION
AN Yes No Yes No AO THER (Including Author, Title, Date, Pertinent Pages, etc.) OTHER (Including Author, Title, Date, Pertinent Pages, etc.) OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Schmidt, W., et al., "Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: A novel general strategy for the generation of potent cancer vaccines," Proc. Natl. Acad. Sci. USA 93:9759-9763 (September 1996). AS J Van Pel, A., and Boon, T., "Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis," Proc. Natl. Acad. Sci. USA 79:4718-4722 (August 1982). AT J Zatloukal, K., et al., "Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'," Gene 135:199-207 (1993).	AM AN AN AN AN AN AN AN AN AN		AL								
AN Yes No AP OTHER (Including Author, Title, Date, Pertinent Pages, etc.) OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Schmidt, W., et al., "Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: A novel general strategy for the generation of potent cancer vaccines," Proc. Natl. Acad. Sci. USA 93:9759-9763 (September 1996). AS Van Pel, A., and Boon, T., "Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis," Proc. Natl. Acad. Sci. USA 79:4718-4722 (August 1982). AT Zatloukal, K., et al., "Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'," Gene 135:199-207 (1993). DATE CONSIDERED LOTTER	AN OTHER (Including Author, Title, Date, Pertinent Pages, etc.) AR AR Schmidt, W., et al., "Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: A novel general strategy for the generation of potent cancer vaccines," Proc. Natl. Acad. Sci. USA 93:9759-9763 (September 1996). AS Van Pel, A., and Boon, T., "Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis," Proc. Natl. Acad. Sci. USA 79:4718-4722 (August 1982). Zatloukal, K., et al., "Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'," Gene 135:199-207 (1993). EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw Line through		AM								1
OTHER (Including Author, Title, Date, Pertinent Pages, etc.) OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Schmidt, W., et al., "Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: A novel general strategy for the generation of potent cancer vaccines," Proc. Natl. Acad. Sci. USA 93:9759-9763 (September 1996). Van Pel, A., and Boon, T., "Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis," Proc. Natl. Acad. Sci. USA 79:4718-4722 (August 1982). AT Zatloukal, K., et al., "Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'," Gene 135:199-207 (1993). EXAMINER DATE CONSIDERED LORMAN	AD OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Schmidt, W., et al., "Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: A novel general strategy for the generation of potent cancer vaccines," Proc. Natl. Acad. Sci. USA 93:9759-9763 (September 1996). Van Pel, A., and Boon, T., "Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis," Proc. Natl. Acad. Sci. USA 79:4718-4722 (August 1982). Zatloukal, K., et al., "Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'," Gene 135:199-207 (1993). EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through				······································						Yes
OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Schmidt, W., et al., "Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: A novel general strategy for the generation of potent cancer vaccines," As Van Pel, A., and Boon, T., "Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis," Proc. Natl. Acad. Sci. USA 79:4718-4722 (August 1982). AT Zatloukal, K., et al., "Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'," Gene 135:199-207 (1993). DATE CONSIDERED LEARNING.	OTHER (Including Author, Title, Date, Pertinent Pages, etc.) AR Schmidt, W., et al., "Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: A novel general strategy for the generation of potent cancer vaccines," Proc. Natl. Acad. Sci. USA 93:9759-9763 (September 1996). Van Pel, A., and Boon, T., "Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis," Proc. Natl. Acad. Sci. USA 79:4718-4722 (August 1982). Zatloukal, K., et al., "Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'," Gene 135:199-207 (1993). EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through										Yes
OTHER (Including Author, Title, Date, Pertinent Pages, etc.) AR Schmidt, W., et al., "Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: A novel general strategy for the generation of potent cancer vaccines," Proc. Natl. Acad. Sci. USA 93:9759-9763 (September 1996). Van Pel, A., and Boon, T., "Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis," Proc. Natl. Acad. Sci. USA 79:4718-4722 (August 1982). Zatloukal, K., et al., "Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'," Gene 135:199-207 (1993). EXAMINER DATE CONSIDERED When	OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Schmidt, W., et al., "Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: A novel general strategy for the generation of potent cancer vaccines," Proc. Natl. Acad. Sci. USA 93:9759-9763 (September 1996). Van Pel, A., and Boon, T., "Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis," Proc. Natl. Acad. Sci. USA 79:4718-4722 (August 1982). Zatloukal, K., et al., "Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'," Gene 135:199-207 (1993). EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through			+							Yes
Schmidt, W., et al., "Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: A novel general strategy for the generation of potent cancer vaccines," AS Van Pel, A., and Boon, T., "Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis," Proc. Natl. Acad. Sci. USA 79:4718-4722 (August 1982). AT Zatloukal, K., et al., "Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'," Gene 135:199-207 (1993). EXAMINER DATE CONSIDERED LEARN.	Schmidt, W., et al., "Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: A novel general strategy for the generation of potent cancer vaccines," Proc. Natl. Acad. Sci. USA 93:9759-9763 (September 1996). Van Pel, A., and Boon, T., "Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis," Proc. Natl. Acad. Sci. USA 79:4718-4722 (August 1982). Zatloukal, K., et al., "Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'," Gene 135:199-207 (1993). EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through		AP								No.
AR 6 Class I peptide ligand: A novel general strategy for the generation of potent cancer vaccines," Proc. Natl. Acad. Sci. USA 93:9759-9763 (September 1996). Van Pel, A., and Boon, T., "Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis," Proc. Natl. Acad. Sci. USA 79:4718-4722 (August 1982). Zatloukal, K., et al., "Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'," Gene 135:199-207 (1993). EXAMINER DATE CONSIDERED 1551	AS 5 Class I peptide ligand: A novel general strategy for the generation of potent cancer vaccines," Proc. Natl. Acad. Sci. USA 93:9759-9763 (September 1996). Van Pel, A., and Boon, T., "Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis," Proc. Natl. Acad. Sci. USA 79:4718-4722 (August 1982). Zatloukal, K., et al., "Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'," Gene 135:199-207 (1993). EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through				OTHER (Including Author	or, Title, Date, Perti	nent Pages, etc	:.)		
variant obtained by mutagenesis," Proc. Natl. Acad. Sci. USA 79:4718-4722 (August 1982). Zatloukal, K., et al., "Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'," Gene 135:199-207 (1993). EXAMINER DATE CONSIDERED Software	variant obtained by mutagenesis," Proc. Natl. Acad. Sci. USA 79:4718-4722 (August 1982). Zatloukal, K., et al., "Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'," Gene 135:199-207 (1993). EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through	m		<u>5</u>	class I pep	tide ligand: A	novel general strateg	y for the gener	major hi ation of	stocompatib potent canc	er vaccines," /
generating 'tumor vaccines'," Gene 135:199-207 (1993). EXAMINER DATE CONSIDERED 1851	generating 'tumor vaccines'," Gene 135:199-207 (1993). EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through	Pm/	AS	<u>5</u>	Van Pel, A., and Boon, T., "Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis," <i>Proc. Natl. Acad. Sci. USA 79</i> :4718-4722 (August 1982).						
8/20/20	EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through	M/	AT &	<u>5</u>	Zatloukal, K., et al., "Somatic gene therapy for cancer: the utility of transferrinfection in generating 'tumor vaccines'," Gene 135:199-207 (1993).						
	EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through	EXAMINER	1	1				DA	TE CONSID	C ISV	n
	EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP out. Draw line through			— <u> </u>					MDED 400	<u> </u>	

••

Page 6 of 6

					ATTY. DOCKET NO. APPLICATION NO. 0652.1710000 09/077,214					
			РТО-1449		APPLICANT SCHMIDT et al.					
<u>IN</u>	FORMATIO	ON DIS	CLOSURE STATE	<u>EMENT</u>	FILING DATE May 26, 1998	FILING DATE GROUP				
				U.S.	. PATENT DOCUMENTS					
EXAMINER INITIAL		חטכוו	MENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE		
INTITAL	AA	1 2000	MENT NOMBER	DATE	NAME	CLASS	30B-CLA33	FIEING DATE		
	АВ									
	AC									
	AD				CIPE					
	AE	ļ			ADD = 6 1000					
	AF	<u> </u>		ļ	ATR 6 1999 C					
	AG	<u> </u>								
	AH	—-	 	 	TRADE					
	AI	 -								
	AJ AK	 			 			 		
	AK	<u></u>		FOREI	GN PATENT DOCUMENTS			L		
EXAMINER		T -	-							
INITIAL	<u> </u>	DOCU	MENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION		
	AL	<u> </u>						Yes No		
<u>-</u> +	АМ	<u> </u>	. Wes					Yes No		
	AN	<u> </u>						Yes No		
	AO	<u> </u>						Yes No		
	AP							Yes No		
			OTHER (Including Author	, Title, Date, Pertinent Pages	, etc.)				
(PB)	AR ♥	<u>6</u>	Zatloukal, an IL-2-Bas	K., et al., "Elio ed Vaccine," J.	citation of a Systemic and Prot Immunol. 154:3406-3419 (April 1	ective Anti 995).	-Melanoma Immu	/		
V^/	AS *	<u>6</u>	Zier, K.S., and Gansbacher, B., "Tumour Cell Vaccines That Secrete Interleukin-2 (IL-2) and Interferony (IFNy) are Recognised by T Cells While Resisting Destruction by Natural Killer (NK) Cells," Eur. J. Cancer 32A:1408-1412 (July 1996).							
	AT	-								
EXAMINER	1/					DATE CONS	IDERED 8/1	U/sem		
EXAMINER: Inicitation if no	tial if	refere formar	ence consider nce and not c	ed, whether or n onsidered. Incl	ot citation is in conformance was ude copy of this form with next	vith MPEP 60	9. Draw line	through ant.		